Advanced search
Publication Cover
Pharmacogenomics Volume 11, 2010 - Issue 8
Submit an article Journal homepage
1,256
Views
17
CrossRef citations to date
0
Altmetric
Perspective

Realities and Expectations of Pharmacogenomics and Personalized Medicine: Impact of Translating Genetic Knowledge into Clinical Practice

Alessio Squassina1 University of Cagliari, Cagliari, ItalyView further author information
,
Mirko Manchia1 University of Cagliari, Cagliari, Italy;2 Dalhousie University, Halifax, Nova Scotia, CanadaView further author information
,
Vangelis G Manolopoulos3 Democritus University of Thrace School of Medicine, Alexandroupolis, GreeceView further author information
,
Mehmet Artac4 Selcuk University, Konya, TurkeyView further author information
,
Christina Lappa-Manakou5 Erasmus University Medical Center, Rotterdam, The NetherlandsView further author information
,
Sophia Karkabouna5 Erasmus University Medical Center, Rotterdam, The NetherlandsView further author information
,
Konstantinos Mitropoulos5 Erasmus University Medical Center, Rotterdam, The NetherlandsView further author information
,
Maria Del Zompo1 University of Cagliari, Cagliari, ItalyView further author information
&
George P Patrinos6 University of Patras, Department of Pharmacy, School of Health Sciences, University Campus, Rion, GR-265 04, Patras, Greece. Tel.: +30 261 096 9834 Fax: +30 261 096 [email protected]View further author information
 show all
Pages 1149-1167 | Published online: 12 Aug 2010

Bibliography

  • Spear BB , Heath-ChiozziM, HuffJ: Clinical application of pharmacogenetics.Trends Mol. Med.7 , 201–204 (2001).
  • Davies EC , GreenCF, MottramDR, PirmohamedM: Adverse drug reactions in hospitals: a narrative review.Curr. Drug Saf.2 , 79–87 (2007).
  • Patrinos GP , GrosveldFG: Pharmacogenomics and therapeutics of hemoglobinopathies.Hemoglobin32 , 229–236 (2008).
  • Severino G , Del Zompo M: Adverse drug reactions: role of pharmacogenomics. Pharmacol. Res.49 , 363–373 (2004).
  • Manolopoulos VG : Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.Clin. Chem. Lab. Med.45 , 801–814 (2007).
  • Roden DM , AltmanRB, BenowitzNL et al.: Pharmacogenomics: challenges and opportunities.Ann. Intern. Med.145 , 749–757 (2006).
  • Giacomini KM , BrettCM, AltmanRB et al.: The pharmacogenetics research network: from SNP discovery to clinical drug response.Clin. Pharmacol. Ther.81 , 328–345 (2007).
  • Piquette-Miller M , GrantDM: The art and science of personalized medicine.Clin. Pharmacol. Ther.81 , 311–315 (2007).
  • Delisi C : Meetings that changed the world: Santa Fe 1986: human genome baby-steps.Nature455 , 876–877 (2008).
  • Shin J , KayserSR, LangaeeTY: Pharmacogenetics: from discovery to patient care.Am. J. Health Syst. Pharm.66 , 625–637 (2009).
  • de Koning P , KeirnsJ: Clinical pharmacology, biomarkers and personalized medicine: education please.Biomark. Med.3 , 685–700 (2009).
  • Roses AD : Pharmacogenetics and drug development: the path to safer and more effective drugs.Nat. Rev. Genet.5 , 645–656 (2004).
  • Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69 , 89–95 (2001).
  • Jain KK : Role of oncoproteomics in the personalized management of cancer.Expert. Rev. Proteomics1(1) , 49–55 (2004).
  • Mok TS , WuYL, ThongprasertS et al.: Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma.N. Engl. J. Med.361 , 947–957 (2009).
  • Rosell R , MoranT, QueraltC et al.: Screening for epidermal growth factor receptor mutations in lung cancer.N. Engl. J. Med.361 , 958–967 (2009).
  • Lievre A , BachetJB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66 , 3992–3995 (2006).
  • Di Fiore F , BlanchardF, CharbonnierF et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy.Br. J. Cancer96 , 1166–1169 (2007).
  • Lievre A , BachetJB, BoigeV et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.J. Clin. Oncol.26 , 374–379 (2008).
  • Amado RG , WolfM, PeetersM et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J. Clin. Oncol.26 , 1626–1634 (2008).
  • Sartore-Bianchi A , MoroniM, VeroneseS et al.: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.J. Clin. Oncol.25 , 3238–3245 (2007).
  • Iyer L , DasS, JanischL et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.Pharmacogenomics J.2 , 43–47 (2002).
  • Artac M , BozcukH, PehlivanS et al.: The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.J. Cancer Res. Clin. Oncol.136 , 803–809 (2010).
  • Hoskins JM , MarcuelloE, AltesA et al.: Irinotecan pharmacogenetics: influence of pharmacodynamic genes.Clin. Cancer Res.14 , 1788–1796 (2008).
  • Relling MV , HancockML, RiveraGK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.J. Natl Cancer Inst.91 , 2001–2008 (1999).
  • Pirmohamed M : Warfarin: almost 60 years old and still causing problems.Br. J. Clin. Pharmacol.62 , 509–511 (2006).
  • James AH , BrittRP, RaskinoCL, ThompsonSG: Factors affecting the maintenance dose of warfarin.J. Clin. Pathol.45 , 704–706 (1992).
  • Bodin L , VerstuyftC, TregouetDA et al.: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood106 , 135–140 (2005).
  • Schalekamp T , BrasseBP, RoijersJF et al.: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.Clin. Pharmacol. Ther.81 , 185–193 (2007).
  • Wadelius M , ChenLY, LindhJD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting.Blood113 , 784–792 (2009).
  • Stehle S , KirchheinerJ, LazarA, FuhrU: Pharmacogenetics of oral anticoagulants: a basis for dose individualization.Clin. Pharmacokinet.47 , 565–594 (2008).
  • Sconce EA , KhanTI, WynneHA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood106 , 2329–2333 (2005).
  • Gage BF , EbyC, JohnsonJA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.Clin. Pharmacol. Ther.84 , 326–331 (2008).
  • Klein TE , AltmanRB, ErikssonN et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data.N. Engl. J. Med.360 , 753–764 (2009).
  • Hillman MA , WilkeRA, YaleSH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.Clin. Med. Res.3 , 137–145 (2005).
  • Caraco Y , BlotnickS, MuszkatM: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Clin. Pharmacol. Ther.83 , 460–470 (2008).
  • Anderson JL , HorneBD, StevensSM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Circulation116 , 2563–2570 (2007).
  • Schwarz UI , RitchieMD, BradfordY et al.: Genetic determinants of response to warfarin during initial anticoagulation.N. Engl. J. Med.358 , 999–1008 (2008).
  • van Schie RM , WadeliusMI, KamaliF et al.: Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Pharmacogenomics10 , 1687–1695 (2009).
  • Ansell J , HirshJ, HylekE, JacobsonA, CrowtherM, PalaretiG: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest133 , S160–S198 (2008).
  • Thomas D , GiuglianoRP: Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.J. Cardiovasc. Pharmacol.51 , 425–433 (2008).
  • Reaume KT , RegalRE, DorschMP: Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.Ann. Pharmacother.42 , 550–557 (2008).
  • Simon DI , JozicJ: Drug-eluting stents and antiplatelet resistance.Am. J. Cardiol.102 , J29–J37 (2008).
  • Gladding P , WebsterM, OrmistonJ, OlsenS, WhiteH: Antiplatelet drug nonresponsiveness.Am. Heart J.155 , 591–599 (2008).
  • Gurbel PA , TantryUS: Aspirin and clopidogrel resistance: consideration and management.J. Interv. Cardiol.19 , 439–448 (2006).
  • Geisler T , SchaeffelerE, DipponJ et al.: CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Pharmacogenomics9(9) , 1251–1259 (2008).
  • Chen BL , ZhangW, LiQ et al.: Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.Clin. Exp. Pharmacol. Physiol35 , 904–908 (2008).
  • Rocca B , PatronoC: Determinants of the interindividual variability in response to antiplatelet drugs.J. Thromb. Haemost.3 , 1597–1602 (2005).
  • Hulot JS , BuraA, VillardE et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood108 , 2244–2247 (2006).
  • Mega JL , CloseSL, WiviottSD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Circulation119 , 2553–2560 (2009).
  • Mega JL , CloseSL, WiviottSD et al.: Cytochrome P-450 polymorphisms and response to clopidogrel.N. Engl. J. Med.360 , 354–362 (2009).
  • Trenk D , HochholzerW, FrommMF et al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.J. Am. Coll. Cardiol.51 , 1925–1934 (2008).
  • Sibbing D , KochW, GebhardD et al.: Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.Circulation121 , 512–518 (2010).
  • Giusti B , GoriAM, MarcucciR, AbbateR: Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Expert. Opin. Drug Metab. Toxicol.6(4) , 393–407 (2010).
  • Collet JP , HulotJS, PenaA et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet373 , 309–317 (2009).
  • Ellis KJ , StoufferGA, McLeodHL, LeeCR: Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Pharmacogenomics10(11) , 1799–1817 (2009).
  • Sim SC , RisingerC, DahlML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther.79 , 103–113 (2006).
  • Ragia G , ArvanitidisKI, TavridouA, ManolopoulosVG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.Pharmacogenomics10 , 43–49 (2009).
  • Arranz MJ , DawsonE, ShaikhS et al.: Cytochrome P4502D6 genotype does not determine response to clozapine.Br. J. Clin. Pharmacol.39 , 417–420 (1995).
  • Riedel M , SchwarzMJ, StrassnigM et al.: Risperidone plasma levels, clinical response and side-effects.Eur. Arch. Psychiatry Clin. Neurosci.255 , 261–268 (2005).
  • de Leon J , SusceMT, PanRM, FairchildM, KochWH, WedlundPJ: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.J. Clin. Psychiatry66 , 15–27 (2005).
  • Kakihara S , YoshimuraR, ShinkaiK et al.: Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.Int. Clin. Psychopharmacol.20 , 71–78 (2005).
  • Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry9 , 442–473 (2004).
  • Murayama N , SoyamaA, SaitoY et al.: Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes.J. Pharmacol. Exp. Ther.308 , 300–306 (2004).
  • Kootstra-Ros JE , SmallegoorW, van der WJ: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann. Clin. Biochem.42 , 216–219 (2005).
  • Charlier C , BrolyF, LhermitteM, PintoE, AnsseauM, PlomteuxG: Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.Ther. Drug Monit.25 , 738–742 (2003).
  • Scordo MG , SpinaE, DahlML, GattiG, PeruccaE: Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.Basic Clin. Pharmacol. Toxicol.97 , 296–301 (2005).
  • Shams ME , ArnethB, HiemkeC et al.: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.J. Clin. Pharm. Ther.31 , 493–502 (2006).
  • Guzey C , SpigsetO: Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.J. Clin. Psychopharmacol.26 , 211–212 (2006).
  • Hinrichs JW , LooversHM, ScholtenB, van der Weide J: Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur. J. Clin. Pharmacol.64 , 979–986 (2008).
  • Rodriguez-Antona C , GurwitzD, de Leon J et al.: CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost–effectiveness studies. Pharmacogenomics10 , 685–699 (2009).
  • Bertilsson L , DahlML, SjoqvistF et al.: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.Lancet341 , 63 (1993).
  • Meyer UA : Pharmacogenetics and adverse drug reactions.Lancet356 , 1667–1671 (2000).
  • Howes OD , EgertonA, AllanV, McGuireP, StokesP, KapurS: Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Curr. Pharm. Des15 , 2550–2559 (2009).
  • Dahmen N , MullerMJ, GermeyerS et al.: Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients.Schizophr. Res.49 , 223–225 (2001).
  • Szekeres G , KeriS, JuhaszA et al.: Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.Am. J. Med. Genet. B Neuropsychiatr. Genet.124B , 1–5 (2004).
  • Adams DH , CloseS, FarmenM, DowningAM, BreierA, HoustonJP: Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Caucasian patients with chronic schizophrenia or schizoaffective disorder.Hum. Psychopharmacol.23 , 267–274 (2008).
  • Schafer M , RujescuD, GieglingI et al.: Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene.Am. J. Psychiatry158 , 802–804 (2001).
  • Arranz MJ , de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12 , 707–747 (2007).
  • Smeraldi E , ZanardiR, BenedettiF, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry3 , 508–511 (1998).
  • Pollock BG , FerrellRE, MulsantBH et al.: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.Neuropsychopharmacology23 , 587–590 (2000).
  • Zanardi R , SerrettiA, RossiniD et al.: Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.Biol. Psychiatry50 , 323–330 (2001).
  • Yu YW , TsaiSJ, ChenTJ, LinCH, HongCJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders.Mol. Psychiatry7 , 1115–1119 (2002).
  • Arias B , CatalanR, GastoC, GutierrezB, FananasL: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.J. Clin. Psychopharmacol.23 , 563–567 (2003).
  • Perlis RH , MischoulonD, SmollerJW et al.: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.Biol. Psychiatry54 , 879–883 (2003).
  • Hong CJ , ChenTJ, YuYW, TsaiSJ: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.Pharmacogenomics J.6 , 27–33 (2006).
  • Mrazek DA , RushAJ, BiernackaJM et al.: SLC6A4 variation and citalopram response.Am. J. Med. Genet. B Neuropsychiatr. Genet.150B , 341–351 (2009).
  • Cusin C , SerrettiA, ZanardiR et al.: Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.Int. J. Neuropsychopharmacol.5 , 27–35 (2002).
  • McMahon FJ , BuervenichS, CharneyD et al.: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.Am. J. Hum. Genet.78 , 804–814 (2006).
  • Kato M , FukudaT, WakenoM et al.: Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.Am. J. Med. Genet. B Neuropsychiatr. Genet.150B , 115–123 (2009).
  • Uher R , Huezo-DiazP, PerroudN et al.: Genetic predictors of response to antidepressants in the GENDEP project.Pharmacogenomics J.9 , 225–233 (2009).
  • Kato M , FukudaT, WakenoM et al.: Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.Neuropsychobiology53 , 186–195 (2006).
  • Ising M , LucaeS, BinderEB et al.: A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.Arch. Gen. Psychiatry66 , 966–975 (2009).
  • Shyn SI , ShiJ, KraftJB et al.: Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies.Mol. Psychiatry DOI: 10.1038/mp.2009.125 (2009) (Epub ahead of print).
  • Uher R , PerroudN, NgMY et al.: Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Am. J. Psychiatry167 , 555–564 (2010).
  • Aral H , Vecchio-SadusA: Toxicity of lithium to humans and the environment – a literature review.Ecotoxicol. Environ. Saf.70 , 349–356 (2008).
  • Cruceanu C , AldaM, TureckiG: Lithium: a key to the genetics of bipolar disorder.Genome Med.1 , 79 (2009).
  • Rybakowski JK , SuwalskaA, CzerskiPM, Dmitrzak-WeglarzM, Leszczynska-RodziewiczA, HauserJ: Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype.Pharmacol. Rep.57 , 124–127 (2005).
  • Serretti A , LilliR, MandelliL, LorenziC, SmeraldiE: Serotonin transporter gene associated with lithium prophylaxis in mood disorders.Pharmacogenomics J.1 , 71–77 (2001).
  • Serretti A , MalitasPN, MandelliL et al.: Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.Pharmacogenomics J.4 , 267–273 (2005).
  • Perlis RH , SmollerJW, FerreiraMA et al.: A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.Am. J. Psychiatry166 , 718–725 (2009).
  • Schulze TG , AldaM, AdliM et al.: The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.Neuropsychobiology62 , 72–78 (2010).
  • Baquero F : Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health.Clin. Infect. Dis.23 , 819–823 (1996).
  • McCaig LF , HughesJM: Trends in antimicrobial drug prescribing among office-based physicians in the United States.JAMA273 , 214–219 (1995).
  • Picard FJ , BergeronMG: Rapid molecular theranostics in infectious diseases.Drug Discov. Today7 , 1092–1101 (2002).
  • Zhang R , ZhangCT: The impact of comparative genomics on infectious disease research.Microbes Infect.8 , 1613–1622 (2006).
  • Behr MA , WilsonMA, GillWP et al.: Comparative genomics of BCG vaccines by whole-genome DNA microarray.Science284 , 1520–1523 (1999).
  • d‘Arminio MA , LepriAC, RezzaG et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients.AIDS14 , 499–507 (2000).
  • Mallal S , PhillipsE, CarosiG et al.: HLA-B*5701 screening for hypersensitivity to abacavir.N. Engl. J. Med.358 , 568–579 (2008).
  • Young B , SquiresK, PatelP et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.AIDS22 , 1673–1675 (2008).
  • Haas DW , RibaudoHJ, KimRB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS18 , 2391–2400 (2004).
  • Brumme ZL , DongWW, ChanKJ et al.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.AIDS17 , 201–208 (2003).
  • Rodriguez-Novoa S , LabargaP, SorianoV: Pharmacogenetics of tenofovir treatment.Pharmacogenomics10 , 1675–1685 (2009).
  • Chung WH , HungSI, HongHS et al.: Medical genetics: a marker for Stevens–Johnson syndrome.Nature428 , 486 (2004).
  • Hung SI , ChungWH, JeeSH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.Pharmacogenet. Genomics16 , 297–306 (2006).
  • Man CB , KwanP, BaumL et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.Epilepsia48 , 1015–1018 (2007).
  • Sissung TM , EnglishBC, VenzonD, FiggWD, DeekenJF: Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.Pharmacogenomics11 , 89–103 (2010).
  • Ruano G , GoetheJW, CaleyC et al.: Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Mol. Psychiatry12 , 474–482 (2007).
  • de Leon J , CorreaJC, RuanoG, WindemuthA, ArranzMJ, DiazFJ: Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophr. Res.98 , 40–46 (2008).
  • Arranz MJ , MunroJ, BirkettJ et al.: Pharmacogenetic prediction of clozapine response.Lancet355 , 1615–1616 (2000).
  • Pace BS , ZeinS: Understanding mechanisms of γ-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction.Dev. Dyn.235 , 1727–1737 (2006).
  • Steinberg MH , LuZH, BartonFB, TerrinML, CharacheS, DoverGJ: Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.Blood89 , 1078–1088 (1997).
  • Yavarian M , KarimiM, BakkerE, HarteveldCL, GiordanoPC: Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients.Haematologica89 , 1172–1178 (2004).
  • Ma Q , WyszynskiDF, FarrellJJ et al.: Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.Pharmacogenomics J.7 , 386–394 (2007).
  • Scheuner MT , SieverdingP, ShekellePG: Delivery of genomic medicine for common chronic adult diseases: a systematic review.JAMA299 , 1320–1334 (2008).
  • Gurwitz D , LunshofJE, DedoussisG et al.: Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.Pharmacogenomics J.5 , 221–225 (2005).
  • Gurwitz D , WeizmanA, RehaviM: Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine.Trends Pharmacol. Sci.24 , 122–125 (2003).
  • Frueh FW , GurwitzD: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.Pharmacogenomics5 , 571–579 (2004).
  • Higgs JE , AndrewsJ, GurwitzD, PayneK, NewmanW: Pharmacogenetics education in British medical schools.Genomic. Med.2 , 101–105 (2008).
  • Julian-Reynier C , NippertI, CalefatoJM et al.: Genetics in clinical practice: general practitioners‘ educational priorities in European countries.Genet. Med.10 , 107–113 (2008).
  • Fargher EA , EddyC, NewmanW et al.: Patients‘ and healthcare professionals‘ views on pharmacogenetic testing and its future delivery in the NHS.Pharmacogenomics8 , 1511–1519 (2007).
  • Tamaoki M , GushimaH, TsutaniK: Awareness survey of parties involved in pharmacogenomics in Japan.Pharmacogenomics8 , 275–286 (2007).
  • Mrazek M , KoenigB, SkimeM et al.: Assessing attitudes about genetic testing as a component of continuing medical education.Acad. Psychiatry31 , 447–451 (2007).
  • Deverka PA , VernonJ, McLeodHL: Economic opportunities and challenges for pharmacogenomics.Annu. Rev. Pharmacol. Toxicol.50 , 423–437 (2010).
  • Perlis RH , PatrickA, SmollerJW, WangPS: When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost–effectiveness analysis based on data from the STAR*D study.Neuropsychopharmacology34 , 2227–2236 (2009).
  • Carlson JJ , GarrisonLP, RamseySD, VeenstraDL: The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.Value Health12 , 20–27 (2009).
  • Priest VL , BeggEJ, GardinerSJ et al.: Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.Pharmacoeconomics.24 , 767–781 (2006).
  • Ginsburg GS , WillardHF: Genomic and personalized medicine: foundations and applications.Transl. Res.154 , 277–287 (2009).
  • Williams MS : Insurance coverage for pharmacogenomics testing in the USA.Pers. Med.4 , 479–487 (2007).
  • Deverka PA , McLeodHL: Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.Clin. Pharmacol. Ther.84 , 191–193 (2008).
  • Flowers CR , VeenstraD: The role of cost–effectiveness analysis in the era of pharmacogenomics.Pharmacoeconomics22 , 481–493 (2004).
  • Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL: A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab. Rev.40 , 377–401 (2008).
  • Matloff ET , ShappellH, BrierleyK, BernhardtBA, McKinnonW, PeshkinBN: What would you do? Specialists‘ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.J. Clin. Oncol.18 , 2484–2492 (2000).
  • Huizenga CR , LowstuterK, BanksKC, LagosVI, VandergonVO, WeitzelJN: Evolving perspectives on genetic discrimination in health insurance among health care providers.Fam. Cancer9(2) , 253–260 (2009).
  • Robertson JA : Consent and privacy in pharmacogenetic testing.Nat. Genet.28 , 207–209 (2001).
  • Issa AM : Ethical perspectives on pharmacogenomic profiling in the drug development process.Nat. Rev. Drug Discov.1 , 300–308 (2002).
  • Morley KI , HallWD: Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.J. Mol. Med.82 , 21–30 (2004).
  • Rothstein MA , EppsPG: Ethical and legal implications of pharmacogenomics.Nat. Rev. Genet.2 , 228–231 (2001).
  • Godard B , CardinalG: Ethical implications in genetic counseling and family studies of the epilepsies.Epilepsy Behav.5 , 621–626 (2004).
  • Vaszar LT , ChoMK, RaffinTA: Privacy issues in personalized medicine.Pharmacogenomics4 , 107–112 (2003).
  • Buchanan A , CalifanoA, KahnJ, McPhersonE, RobertsonJ, BrodyB: Pharmacogenetics: ethical issues and policy options.Kennedy. Inst. Ethics J.12 , 1–15 (2002).
  • Smart A , MartinP, ParkerM: Tailored medicine: whom will it fit? The ethics of patient and disease stratification.Bioethics.18 , 322–342 (2004).
  • Slaughter LM : The Genetic Information Nondiscrimination Act: why your personal genetics are still vulnerable to discrimination.Surg. Clin. North Am.88 , 723–38, vi (2008).
  • Braff JP , ChatterjeeB, HochmanM et al.: Patient-tailored medicine, part two: personalized medicine and the legal landscape.J. Health Life Sci. Law2 , 1–43 (2009).
  • Obama B : The Genomics and Personalized Medicine Act of 2006.Clin. Adv. Hematol. Oncol.5 , 39–40 (2007).
  • Dressler LG , TerrySF: How will GINA influence participation in pharmacogenomics research and clinical testing?Clin. Pharmacol. Ther.86 , 472–475 (2009).
  • Lee SS , MudaliarA: Medicine. Racing forward: the Genomics and Personalized Medicine Act.Science323 , 342 (2009).
  • van Rijn MJ , van Duijn CM, Slooter AJ: Impact of genetic testing on complex diseases. Eur. J. Epidemiol.20 , 383–388 (2005).
  • Manolio TA , CollinsFS, CoxNJ et al.: Finding the missing heritability of complex diseases.Nature461 , 747–753 (2009).
  • Pierce BL , AhsanH: Case-only genome-wide interaction study of disease risk, prognosis and treatment.Genet. Epidemiol.34 , 7–15 (2010).
  • Pacheu-Grau D , Gomez-DuranA, Lopez-PerezMJ, MontoyaJ, Ruiz-PesiniE: Mitochondrial pharmacogenomics: barcode for antibiotic therapy.Drug Discov. Today15 , 33–39 (2010).
  • Blanc H , AdamsCW, WallaceDC: Different nucleotide changes in the large rRNA gene of the mitochondrial DNA confer chloramphenicol resistance on two human cell lines.Nucleic Acids Res.9 , 5785–5795 (1981).
  • King MP , AttardiG: Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA.Cell52 , 811–819 (1988).
  • Luca CC , LamBL, MoraesCT: Erythromycin as a potential precipitating agent in the onset of Leber‘s hereditary optic neuropathy.Mitochondrion4 , 31–36 (2004).
  • Girnita DM , BurckartG, ZeeviA: Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation.Curr. Opin. Immunol.20 , 614–625 (2008).
  • Abrahams E , GinsburgGS, SilverM: The Personalized Medicine Coalition: goals and strategies.Am. J. Pharmacogenomics5 , 345–355 (2005).
  • Koslow SH , WilliamsLM, GordonE: Personalized medicine for the brain: a call for action.Mol. Psychiatry15(3) , 229–230 (2010).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.